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ESTIMATION OF STUDY POPULATION SIZE FOR
EFFECTIVENESS OUTCOMES AT 6 AND 12 MONTHSVIA
ELECTRONIC MEDICAL RECORDS
McAdam-Marx C, Brixner D, Oberg B
The University of Utah College of Pharmacy, Salt Lake City, UT, USA
The lag between product launch and prescribing impacts
research timing. This will describe methods applied to a popula-
tion treated with a new antidiabetic agent, exenatide, to project
patient counts for 6 months and 12 months real-world outcomes
analyses. Patients prescribed exenatide via the General Electric
Electronic Medical Record (EMR) database by March 31, 2007
were identiﬁed. The proportions of patients remaining active 6
months and 12 months on March 31, 2007 and with baseline
and follow-up hemoglobin A1C values were identiﬁed. Starts for
2Q07 were estimated based on 4Q06 to 1Q07 growth, and the
number of patients who would have started exenatide at least 6
months or 12 months before December 31, 2007 was projected.
Rates and portions with A1C values were applied to these counts
to predict how many would be active at least 6 months and 12
months on December 31, 2007 and have outcomes data.
Exenatide was prescribed for 8372 patients through March 31,
2007. A total of 5392 and 2240 started exenatide at least 6
months or 12 months prior to March 31, 2007. A total of 2853
(52.9%) had 6 months and 1152 (51.4%) had 12 months activ-
ity. Of these 1721 (60.3%) and 789 (68.5%) had baseline and
follow-up A1C readings. The rate for 1Q07 was 20%; thus the
estimated number prescribed exenatide by the end of 2Q07 was
10,043. Thus, 10,043 and 6946 would be prescribed exenatide at
least 6 months and 12 months before December 31, 2007. Of
these, 3207 and 2447 would be active and have baseline and
follow-up A1C values. Estimates based on prescribing growth
and patient retention was used to estimate patient counts for
outcomes analysis. This facilitates research and planning for
research on a new product. A validation of estimates will be
conducted and reported when available.
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COMPARISON OF CLINICAL EFFECTIVENESS AND SAFETY
OF GLULISINEVERSUS INSULIN LISPRO,ASPART AND
REGULAR HUMAN INSULIN IN PATIENTSWITHTYPE 1 AND
2 DIABETES
Walczak J1, Borowiack E1, Kolodziej K1, Lis J2, Gierczynski J2,
Nogas G1
1Arcana Institute, Cracow, Poland, 2Sanoﬁ-Aventis sp. z o.o,Warszawa,
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OBJECTIVE: The aim of this analysis was to compare clinical
effectiveness of insulin glulisine versus insulin lispro, aspart and
regular human insulin in patients with type 1 and 2 diabetes.
METHODS: The clinical effectiveness was analyzed according to
guidelines of Cochrane Collaboration and HTA Agency in
Poland (AOTM). The comparison of insulin glulisine with com-
parators was performed as direct comparisons. RESULTS:
Patients with type 1 diabetes: There was no statistically signiﬁ-
cant difference between insulin glulisine and insulin lispro, aspart
and regular human insulin in change in mean HbA1c from base-
line. Also there was no statistically signiﬁcant difference between
groups in number of patients with hypoglycemia (overall, noc-
turnal and severe). The comparison of safety parameters for
insulin glulisine versus insulin lispro, aspart and regular human
insulin didn’t show signiﬁcant differences between analyzed
groups. Patient with type 2 diabetes: Meta-analysis of two clini-
cal trials showed no statistically signiﬁcant difference between
insulin glulisine and regular human insulin in change of mean
HbA1c. However in one study there was statistically signiﬁcant
difference in favour of insulin glulisine compared to regular
human insulin in change of HbA1c -0.11%(95% CI: -0.21;
-0.008) after 26 week of follow up. There was relevant difference
between the two groups in favour of insulin glulisine in reporting
of nocturnal hypoglycemia OR: 0.73 (95% CI: 0.57; 0.94). Fre-
quency of adverse events was comparable between groups.
CONCLUSION: Insulin glulisine has efﬁcacy comparable to
insulin aspart, lispro and regular human insulin in patients with
type 1 diabetes. Insulin glulisine, in comparison with regular
human insulin is more effective in treatment of patients with type
2 diabetes. There are no differences in safety between analyzed
comparators.
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EVALUATION OF INSULIN CONTAINING ANTI-DIABETIC
REGIMENS IN HIGH-RISK CARDIOVASCULAR PATIENTSWITH
A PRE-TREATMENT A1C MEASUREMENT GREATERTHAN 9%
Livengood K
University of Southern California, Los Angeles, CA, USA
OBJECTIVE: The purpose of this analysis was to determine if
high-risk cardiovascular patients with concomitant diabetes and
a pre-treatment A1c measurement greater than 9% experienced
better outcomes with insulin containing anti-diabetic medication
regimens than similar patients not taking insulin. METHODS:
High-risk cardiovascular patients with concomitant diabetes and
a pre-treatment A1c measurement of greater than 9% from a
large western United States integrated health care system were
evaluated for an A1c measurement at least three months prior to
treatment initiation and a follow-up measurement at least three
months following initiation. In the case of patients taking insulin,
the three month follow-up period started with the initiation of
insulin. Change in A1c resulting from medication treatment was
evaluated using a two-step endogenous treatment regression
model, with insulin as the endogenous treatment variable. Exog-
enous independent variables included hypertension diagnosis,
hyperlipidemia diagnosis, age, gender, and distance from treat-
ment goal (A1c less than 7%) at baseline. Standard errors for
beta coefﬁcients were computed using HCCM3. RESULTS: Of
11,181 diabetic patients, 707 (314 on insulin) patients met the
inclusion criteria. Although both insulin and non-insulin contain-
ing treatment regimens reduced A1c from baseline to follow-up,
patients on insulin were associated with a greater reduction in
A1c than patients not on insulin. The difference in change was
2.6% and was statistically signiﬁcant (p = 0.0029). CONCLU-
SION: Use of insulin in an anti-diabetic regimen in high-risk
cardiovascular patients with concomitant diabetes and a pre-
treatment A1c greater than 9% resulted in a signiﬁcantly greater
reduction in A1c compared to patients not taking insulin.
PDB8
DEFINING HYPOGLYCEMIA AND ASSESSING ITS AFFECT ON
OUTCOMES INTHE HOSPITAL SETTING
Curkendall SM1,Alexander CM2, Haidar T1, Natoli JL3, Dubois RW3,
Nathanson BH4
1Cerner LifeSciences,Vienna,VA, USA, 2Merck,White House Station,
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Longmeadow, MA, USA
Quantify the impact of hypoglycemia on outcomes of hospital-
ized diabetic patients and determine how variations in the deﬁ-
nition of hypoglycemia affect outcomes. This study used an EMR
database of inpatient and ED encounters for adults with diabetes
treated at 70 hospitals during 2000–2006. Patients presenting to
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the ED and subsequently admitted as inpatients were considered
as one encounter. Encounters with hypoglycemia were catego-
rized into 3 mutually exclusive groups: 1) encounters due to
hypoglycemia required a primary inpatient diagnosis or any ED
diagnosis of hypoglycemia (ICD-9-CM code 251.0, 251.1, or
251.2); 2) encounters in which patients presented with hypogly-
cemia (ie, ﬁrst lab blood glucose [BG] during the ﬁrst 24 hours in
the hospital < 70 mg/dL); and 3) encounters in which patients
developed hypoglycemia only after the ﬁrst 24 hours in the
hospital. Outcomes were total charges, length of stay, discharge
to a skilled nursing facility (SNF), and inpatient mortality.
Encounter types 2 and 3 were each compared with encounters
without hypoglycemia (ie, all BG values 70 mg/dL). Compari-
sons were adjusted for potential confounders (e.g., reasons for
hospitalization, comorbidities, propensity score for hypoglyce-
mia) using multivariate regression models. Hypoglycemia was
rarely used as a primary diagnosis. Of 519,317 encounters
(n = 215,922 diabetic patients), 732 (0.14%) had hypoglycemia
as the reason for the encounter, and most (91%) were ED only
without admission. However, in 8971 encounters (1.73%),
patients presented with hypoglycemia. In an additional 19,487
encounters (3.75%), patients developed hypoglycemia. All out-
comes for patients who developed hypoglycemia were signiﬁ-
cantly different than those for patients without hypoglycemia.
However, only charges and odds of discharge to a SNF were
signiﬁcantly associated with presentation with hypoglycemia.
The effect of hypoglycemia on outcomes depends on when
hypoglycemia is deﬁned and is more pronounced in patients who
developed hypoglycemia than in patients who presented with
hypoglycemia.
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TYPE 2 DIABETES INYOUTH: 2002 AND 2006 PREVALENCE
AND OBESITY IN A PRIMARY CARE SETTING
McAdam-Marx C1, Brixner D1, Field R2, Metraux S2
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OBJECTIVE: This study estimates the prevalence of type 2 dia-
betes (T2DM) in youth treated in a primary care setting. Pub-
lished prevalence estimates range from 0.2 to 1.5 per 1000,
varying by estimation population. This study also quantiﬁes the
association between T2DM and obesity and seeks to conﬁrm
clinical links that have been established between T2DM among
youth and obesity. METHODS: A cross-sectional analysis was
conducted in the General Electric Electronic Medical Record
(EMR) database in 2002 and 2006. The prevalence population
included youth aged 5 to 19 with continuous database activity
during the year. T2DM included two T2DM ICD-9 codes, one
T2DM ICD-9 code and a prescription for insulin, a prescrip-
tion for an oral antidiabetic agent, or two fasting blood glucose
levels 126 mg/dl during or prior to the estimation year,
without type 1 diabetes or polycystic ovary syndrome. Findings
were stratiﬁed by baseline BMI. The odds of developing T2DM
by BMI category were estimated by logistic regression.
RESULTS: The 2002 and 2006 prevalence populations
included 89,087 and 107,857 youth respectively. The preva-
lence of T2DM per 1000 was 2.20 in 2002 and 4.45 in 2006.
Of those with a baseline BMI reading, 8.0% and 9.4% were
obese (BMI > 30 kg/m2) in 2002 and 2006 respectively. T2DM
prevalence in the obese was 6.8 and 22.7 per 1000 in 2002 and
2006 respectively; age, gender and race adjusted odds of the
obese developing T2DM relative to the normal weight popula-
tion were 6.56 and 11.49 in 2002 and 2006 respectively
(P < 0.001 for both). CONCLUSION: Obesity substantially
increases T2DM risks. The prevalence of T2DM in a popula-
tion of youth routinely treated in a primary care setting is
higher than other recent estimates and increased dramatically in
a four year time frame. Additional research is warranted
to identify treatment trends and outcomes in youth with
T2DM.
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OBESITY IS MORE PREVALENT AMONG ABORIGINALSWITH
DIABETES AS COMPAREDTO ALL CANADIANSWITH
DIABETES
Beard K1, Folia C1, Frial T2, Liovas A3
1Agro Health Associates, Burlington, ON, Canada, 2AstraZeneca
Canada, Mississauga, ON, Canada, 3AstraZeneca Canada Inc,
Mississauga, ON, Canada
OBJECTIVE: The rate of heart disease is 1.5-fold greater among
Aboriginals compared to the general Canadian population. Risk
factors such as smoking, hypertension, dyslipidemia, obesity and
diabetes are also more prevalent. For example, type 2 diabetes is
3.6–5.3 times more prevalent among Aboriginals. Obesity is
relatively common in diabetes, contributing to poor diabetes
control and the development of its associated complications. It is
of interest to compare the prevalence of obesity among Aborigi-
nals with diabetes to all Canadians with diabetes. METHODS: A
MEDLINE search was conducted (1966–2007) using the follow-
ing MeSH terms: Indians—North American, Canada, diabetes
mellitus, obesity and body mass index (BMI). Population-based
studies reporting the proportion of Aboriginals with diabetes
that were overweight (e.g.25 kg/m2 for women,27 kg/m2 for
men) or obese (30 kg/m2) were retrieved. Prevalence estimates
of elevated BMIs for Canadians with diabetes were obtained
from the LCDC National Population Survey (1996–1997) and
the Ontario Diabetes Database (1996–1997; Ontario Health
Survey). RESULTS: Twenty-three studies were retrieved. Seven-
teen studies were excluded because either the patient populations
or deﬁnitions of obesity/overweight differed between studies.
Ranges of 76.2–86.5% of Aboriginals with diabetes were either
overweight or obese compared to 59.4% of all Canadians with
diabetes. Furthermore, 44.1–69.6% of Aboriginals with diabetes
were obese compared to 28.6% of all Ontarians with diabetes.
CONCLUSION: When compared with the general Canadian
population with diabetes, elevated BMI is more commonly
observed among Aboriginals with diabetes. These ﬁndings
suggest that obesity, as a risk factor for poor diabetes control and
heart disease, is not optimally managed within the Aboriginal
diabetes population and may pose a great burden to the Aborigi-
nal community. The precise impact of obesity and diabetes on the
health of Aboriginals warrants further research.
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PREVALENCE OF AND RISK FACTORS FOR
HOSPITALIZATIONS IN PATIENTSWITHTYPE 2 DIABETES IN
SOUTH KOREA
Kim CM1, Choi IS2, Jung JC3, Barone JA2, Kim CM4, Suh DC2
1Catholic University, Sucho-gu, Seoul, South Korea, 2Rutgers University,
Piscataway, NJ, USA, 3Korea National Health Insurance Corporation,
Mapo-gu, Seoul, South Korea, 4Merck Global Human heath,
Whitehouse Station, NJ, USA
OBJECTIVE: To estimate prevalence of hospitalizations in dia-
betic patients, to determine factors which inﬂuence hospitaliza-
tions attributable to diabetes, and to calculate length of stay
(LOS) using health insurance claims data. METHODS: This
retrospective cohort study used health insurance claims data
collected from three Catholic University Medical Centers in
South Korea. Type 2 diabetes patients were identiﬁed if patients
received treatment for diabetes (ICD-10 code of E11x) at least
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